CELH Stock Analysis: Celsius Holdings | NASDAQ
Beverages - Non-Alcoholic | NASDAQ, USA | Market Cap: 6.989m USD | 12M Return: -48.7% | US15118V2079 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 293M
EPS Trend: 19.7%
Qual. Beats: 0
Rev. Trend: 90.1%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Celsius Holdings, Inc. (NASDAQ: CELH) is a U.S.-based functional energy drink company that develops, manufactures, markets, sells, and distributes its products across the United States, North America, Europe, Asia Pacific, and other international markets. The company offers a range of products including ready-to-drink energy beverages, hydration powders and sticks, and nutrition and wellness items under the CELSIUS, Alani Nu, and Rockstar brand names, with sub-lines such as CELSIUS ESSENTIALS (formulated with amino acids) and CELSIUS Hydration (zero-sugar electrolyte powders in fruit-forward flavors). The company was founded in 2004, is headquartered in Boca Raton, Florida, and operates a broad omnichannel distribution network spanning direct-to-store delivery, independent distributors, supermarkets, convenience and drug stores, food service providers, mass merchants, fitness centers, club and vitamin specialty stores, and e-commerce platforms.
The company operates within the Consumer Staples sector, specifically the Soft Drinks & Non-alcoholic Beverages sub-industry, a mature and highly competitive category traditionally dominated by large incumbents such as Coca-Cola and PepsiCo. Within this space, Celsius has positioned itself in the faster-growing functional and better-for-you beverage segment, targeting active-lifestyle and fitness-oriented consumers through fitness-center and specialty-channel distribution as well as digital channels.
- Alani Nu acquisition accelerates revenue growth and expands consumer base
- Pepsi distribution partnership drives shelf space expansion nationally
- GLP-1 drug adoption pressures functional beverage category demand
| Net Income: 110.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.40 > 1.0 |
| NWC/Revenue: 27.31% < 20% (prev 43.89%; Δ -16.58% < -1%) |
| CFO/TA 0.10 > 3% & CFO 508.6m > Net Income 110.2m |
| Net Debt (56.3m) to EBITDA (232.9m): 0.24 < 3 |
| Current Ratio: 1.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (256.9m) vs 12m ago 8.33% < -2% |
| Gross Margin: 48.76% > 18% (prev 50.53%; Δ -1.77% > 0.5%) |
| Asset Turnover: 67.99% > 50% (prev 43.91%; Δ 24.08% > 0%) |
| Interest Coverage Ratio: 3.61 > 6 (EBIT TTM 195.9m / Interest Expense TTM 54.3m) |
| A: 0.16 (Total Current Assets 1.88b - Total Current Liabilities 1.04b) / Total Assets 5.17b |
| B: 0.06 (Retained Earnings 313.2m / Total Assets 5.17b) |
| C: 0.04 (EBIT TTM 195.9m / Avg Total Assets 4.48b) |
| D: 1.34 (Book Value of Equity 2.96b / Total Liabilities 2.21b) |
| Altman-Z'' = 2.95 = A |
| DSRI: 0.82 (Receivables 735.3m/490.4m, Revenue 3.05b/1.67b) |
| GMI: 1.04 (GM 50.53% / 48.76%) |
| AQI: 1.00 (AQ_t 0.62 / AQ_t-1 0.61) |
| SGI: 1.83 (Revenue 3.05b / 1.67b) |
| TATA: -0.08 (NI 110.2m - CFO 508.6m) / TA 5.17b) |
| Beneish M = -2.55 (Cap -4..+1) = A |
As of August 16, 2026, the stock is trading at USD 29.09 with a total of 13,421,997 shares traded. Over the past week, the price has changed by +4.75%, over one month by -3.48%, over three months by +0.28% and over the past year by -48.67%.
Current recommended Stop Loss: 26.10 (which is 10.3% or 1.7 ATR below the current price).
Celsius Holdings has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CELH.
- StrongBuy: 8
- Buy: 6
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 41.6 | 42.8% |
P/E Trailing = 120.087
P/E Forward = 18.5185
P/S = 2.2935
P/B = 5.7396
P/EG = 0.292
Revenue TTM = 3.05b USD
EBIT TTM = 195.9m USD
EBITDA TTM = 232.9m USD
Long Term Debt = 667.9m USD (from longTermDebt, last quarter)
Short Term Debt = 7.00m USD (from shortTermDebt, two quarters ago)
Debt = 687.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 19.7m
Net Debt = 56.3m USD (calculated: Debt 687.6m - CCE 631.2m)
Enterprise Value = 7.05b USD (6.99b + Debt 687.6m - CCE 631.2m)
Interest Coverage Ratio = 3.61 (Ebit TTM 195.9m / Interest Expense TTM 54.3m)
EV/FCF = 15.22x (Enterprise Value 7.05b / FCF TTM 462.8m)
FCF Yield = 6.57% (FCF TTM 462.8m / Enterprise Value 7.05b)
FCF Margin = 15.19% (FCF TTM 462.8m / Revenue TTM 3.05b)
Net Margin = 3.62% (Net Income TTM 110.2m / Revenue TTM 3.05b)
Gross Margin = 48.76% ((Revenue TTM 3.05b - Cost of Revenue TTM 1.56b) / Revenue TTM)
Gross Margin QoQ = 48.13% (prev 48.31%)
Tobins Q-Ratio = 1.36 (Enterprise Value 7.05b / Total Assets 5.17b)
Interest Expense / Debt = 7.90% (Interest Expense 54.3m / Debt 687.6m)
Taxrate = 8.84% (12.5m / 141.6m)
NOPAT = 178.6m (EBIT 195.9m * (1 - 8.84%))
Current Ratio = 1.80 (Total Current Assets 1.88b / Total Current Liabilities 1.04b)
Debt / Equity = 0.23 (Debt 687.6m / totalStockholderEquity, last quarter 2.96b)
Debt / EBITDA = 0.24 (Net Debt 56.3m / EBITDA 232.9m)
Debt / FCF = 0.12 (Net Debt 56.3m / FCF TTM 462.8m)
Total Stockholder Equity = 2.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.46% (Net Income 110.2m / Total Assets 5.17b)
RoE = 4.36% (Net Income TTM 110.2m / Total Stockholder Equity 2.53b)
RoCE = 6.13% (EBIT 195.9m / Capital Employed (Equity 2.53b + L.T.Debt 667.9m))
RoIC = 4.50% (NOPAT 178.6m / Invested Capital 3.97b)
WACC = 9.59% (E(6.99b)/V(7.68b) * Re(9.82%) + D(687.6m)/V(7.68b) * Rd(7.90%) * (1-Tc(0.09)))
Discount Rate = 9.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 47.56 | Cagr: 3.55%
[DCF] Terminal Value 74.08% ; FCFF base≈362.0m ; Y1≈415.0m ; Y5≈610.7m
[DCF] Fair Price = 29.60 (EV 7.55b - Net Debt 56.3m = Equity 7.49b / Shares 253.0m; r=9.59% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 19.70 | EPS CAGR: 16.06% | SUE: -0.24 | # QB: 0
Revenue Correlation: 90.15 | Revenue CAGR: 40.71% | SUE: -1.44 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.35 | Chg30d=-19.30% | Revisions=-36% | Analysts=18
EPS current Year (2026-12-31): EPS=1.44 | Chg30d=-10.97% | Revisions=-50% | GrowthEPS=+7.8% | GrowthRev=+26.2%
EPS next Year (2027-12-31): EPS=1.74 | Chg30d=-12.96% | Revisions=-44% | GrowthEPS=+20.4% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: -50% (up=8, down=27)